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Malaria control, and that of other insect borne diseases such as dengue, is
heavily dependent on our ability to control the mosquito populations that
transmit these diseases. The major push over the last decade to reduce the
global burden of malaria has been driven by the distribution of pyrethroid
insecticide-treated bednets and an increase in coverage of indoor residual
spraying (IRS). This has reduced malaria deaths by a third. Progress towards
the goal of reducing this further is threatened by lack of funding and the selec-
tion of drug and insecticide resistance. When malaria control was initially
scaled up, there was little pyrethroid resistance in the major vectors, today
there is no country in Africawhere the vectors remain fully susceptible to pyr-
ethroids. The first pyrethroid resistance mechanisms to be selected produced
low-level resistance which had little or no operational significance. More
recently, metabolically based resistance has been selected, primarily in West
Africa, which in some mosquito populations produces more than 1000-fold
resistance. As this spreads the effectiveness of pyrethroid-based bednets
and IRS will be compromised. New public health insecticides are not readily
available. The pipeline of agrochemical insecticides that can be re-purposed
for public health dried up 30 years ago when the target product profile for
agricultural insecticides shifted from broad spectrum, stable, contact-acting
insecticides to narrow spectrum stomach poisons that could be delivered
through the plant. A public–private partnership, the Innovative Vector Con-
trol Consortium, was established in 2005 to stimulate the development of
new public health pesticides. Nine potential new classes of chemistry are in
the pipeline, with the intention of developing three into new insecticides.
While this has been successfully achieved, it will still take 6–9 years for new
insecticides to reach the market. Careful management of the resistance situ-
ation in the interim will be needed if current gains in malaria control are not
to be reversed.1. Introduction
Malaria is still a major health issue in much of the world with around 660 000
deaths and 219 million cases still occurring in 2010 [1]. This represents a major
improvement over the past decade with a 33% reduction in malaria deaths in
Africa, where 90% of the world’s malaria deaths occur, with massive scaling
up of disease prevention activities linked to attempting to fulfil the Millennium
Development Goals (MDGs) of reduced maternal and child mortality. Malaria
features as a specific indicator for MDG 6 and also contributes to other MDGs,
including poverty, child survival, maternal health and education. The majority
of malaria prevention activities centre around controlling the mosquito vectors
by indoor residual spraying (IRS) of houses with long-lasting insecticide formu-
lations, or reducing the ability of the insects to bite people by encouraging them
to sleep under long-lasting insecticide-treated bednets (LLINs).
The World Health Organisation (WHO) estimates that in the decade
2000–2010, 274 million cases of malaria and 1.1 million deaths, the majority in
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vented by these activities. Over this period, LLIN use rose
from 3% in 2000 to 53% in 2011, where it reached a plateau.
To achieve universal coverage with LLINs, 780 million
people at risk of malaria would need to have access in
Africa, and 150 million bed nets would need to be delivered
each year. This calculation assumes that nets remain effective
on average for 5 years. In 2012, this target was not met with
only 66 million nets being distributed. There is also a growing
body of evidence which suggests that the LLINs are unlikely to
last for 5 years [2,3]. The LLIN market is very price sensitive,
and cheaper nets with lower tensile strength have dominated
the market, resulting in nets that tear and become unusable
well before the projected 5 year life expectancy is reached.
IRS rose from 5% in 2005 to 11% in 2011, representing
153 million people protected globally, 77 million of these in
Africa [1]. The increasewas largely due to the efforts of the Pre-
sident’s Malaria Initiative (PMI) in 19 focus African countries,
with 30.3 million people protected by IRS in 2012 [4].
If we are to maintain these improvements in disease con-
trol and push towards regional elimination and eventual
global eradication of malaria, then funding levels to support
control efforts and operational activities need to be increased
substantially. In order to reach the required global malaria
targets, an estimated US$5.1 billion will be needed every
year from 2011 to 2020. In 2011, only US$2.3 billion was avail-
able, less than half the figure needed. This has improved
recently with increased commitments in December 2013,
with US$12 billion pledged against the US$ 15 billion
needed for 2014–2016 for the Global Fund [5]. However, an
increase in financial support alone will not be enough. We
need to exert better stewardship of the insecticides and
drugs needed to prevent and treat the disease, to ensure
that they remain viable in the medium to long term. If we
do not do this now, then resistance will inevitably reduce
our ability to prevent and control malaria.2. Resistance management
Resistance to both drugs and insecticides is becoming a major
issue. The epicentre of drug resistance is in Southeast Asia,
where resistance to the first line artemisinin combination
therapy (ACT) treatments was selected in Cambodia and has
since spread to neighbouring countries [6]. Monitoring this
resistance is not simple as there are currently no easy markers
that can be tracked. ACT resistance is suspected when an
increase in parasite clearance times is observed and more
than 10% of malaria cases still have detectable parasitaemia 3
days after ACT treatment. The threat this resistance poses to
our ability to treat malaria resulted in the WHO establishing
the Global Plan for Artemisinin Containment (GPARC) in
2011 [7]. While this resistance is a growing issue in Asia, it
has yet to be detected as a major issue in Africa.
By contrast, insecticide resistance is already amajor issue in
Africa. In Africa, where the greatest burden of malaria mor-
tality occurs, there are two major malaria vectors, Anopheles
gambiae and An. funestus, although several secondary vectors
occur, which can take on a primary role. An. gambiae M and
S forms have now been recognized as separate species,
An. gambiae (S form) and An. coluzzi (M form) [8]. Throughout
much of sub-Saharan Africa, these vectors occur [9], although
their importance may shift temporally [10]. An. gambiaebreeds in small temporary water bodies and semi-permanent
sites without vegetation, and densities fluctuate, increasing in
the rainy seasons which produce abundant breeding sites,
whereas An. funestus uses larger bodies of permanent clean
water that are fringed with vegetation. An. gambiae is much
easier to colonize and handle in the laboratory, and because
of this, and the historical easewithwhichAn. funestuswas con-
trolled with DDT in the 1960s,An. funestuswaswrongly felt by
many to be a less important vector.
Current practices in malaria prevention are a classic
example of poor product stewardship likely to lead to the
rapid selection and spread of resistance. In many ways, the
pyrethroids are ideal insecticides for preventing biting and
controlling mosquitoes. They act rapidly, many pyrethroids
have both a repellent and a killing function, they are rela-
tively safe for use in close proximity to humans, and they
are easy to formulate and relatively cheap to produce. No
other insecticide class combines this set of desirable charac-
teristics. This makes them the insecticide class of choice for
disease prevention. Today, all LLINs and more than 80% of
IRS campaigns use pyrethroids. This represents a major selec-
tion pressure for pyrethroid resistance, with the inevitable
result that we have moved from pyrethroid resistance being
a rare occurrence in sub-Saharan African malaria vectors in
2000 to the present time, when no African country has fully
pyrethroid susceptible malaria vectors. Resistance is now
widespread in both An. gambiae and An. funestus, but the
intensity and diversity of the resistance selected vary with
location and species [11,12].
The extent of selection and spread of pyrethroid resistance
has now prompted the WHO to publish the Global Plan for
Insecticide Resistance Management (GPIRM) [13], which is
a concerted call to action and aims to provide guidance to
countries on how to develop and implement an insecticide
resistance management plan within their operational malaria
control activities.
Pyrethroid resistance has occurred in waves and we have
been fortunate that the resistance selected initially has been low
level and has had little obvious impact on the effectiveness of
pyrethroid-based IRS or LLINs. This situation is now changing
rapidly. The initial wave of pyrethroid resistance was primarily
a re-selectionof anoldDDTresistancemechanism inAn. gambiae.
DDTandpyrethroids have a commonmode of action, binding to
the sodium channels on the nerve membranes. Two common
mutations on the sodium channel involving a leucine residue
being converted to phenylalanine or serine produce the
common ‘kdr’ phenotypes, with insects being less susceptible
to the insecticide and more difficult to rapidly knock down
after pyrethroid exposure. Often referred to as the West or East
African forms of kdr in An. gambiae, indicating the locations in
which the respective mutations were first detected, these
mutations have actually arisen multiple times and spread from
different nodes [14], becoming the dominant phenotype in An.
gambiae in many parts of Africa. The mutations produced by a
simple base change can easily be detected using simple PCR.
The ease of monitoring in this form has resulted in several
groups using this as a surrogate for comprehensive resistance
monitoring, with the potential for under-reporting of true resist-
ance levels. Kdr, although common in many insect species, has
not been selected to date in An. funestus.
There is no convincing evidence that kdr alone produces
operationally significant levels of pyrethroid resistance. This
is in direct contrast to the situation in houseflies, where
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the market for pyrethroid-based housefly control products
[15]. Experimental hut studies with LLINs suggested little
or no impact of kdr on the ability of the resistant mosquitoes
to take a blood meal. Similarly, the national malaria control
programme in Equatorial Guinea were able to re-instate
pyrethoid-based IRS in 2013, despite a high frequency of
kdr in An. gambiae, as part of their evidence-based insecticide
resistance management plan [16].
The second wave of resistance selection produced multiple
origins of metabolically based mechanisms of pyrethroid
resistance in both major vectors. The first major reported
instance of this was in An. funestus in Mozambique, where a
cytochrome P450-based mechanism was detected in 1999 in
Kwazulu Natal province [17]. This resistance also occurs in
neighbouring Mozambique [18] and was recently detected in
An. funestus in Malawi [19]. It produces an order of magnitude
higher resistance to pyrethroids than kdr, with a low level of
cross-resistance to the carbamate insecticide, bendiocarb [17].
It is unclear whether this resistance had a direct impact on dis-
ease control, as although its selection coincided with a major
resurgence of malaria in South Africa, resistance to first line
sulfadoxine–pyrimethamine drug treatmentwas also detected
at about the same time and the relative contributions of
both resistances are impossible to disentangle. Operationally,
however this produced a change in insecticide use policy,
with the national programmes in South Africa, Mozambique
and Swaziland shifting to bendiocarb or DDT to counter the
pyrethroid resistance [20].
In An. Gambiae, the first documented metabolic pyre-
throid resistance in East Africa was relatively low level [21],
but was followed soon after by reports of higher level meta-
bolic resistance in West Africa, commensurate with that seen
in South African An. funestus. In all cases, these resistances
were linked to upregulation of cytochrome P450s which
were subsequently shown to metabolize pyrethroids [22].
However, as these metabolic enzymes sit within very large
multi-gene families that are part of the normal cellular
machinery for detoxifying xenobiotics, and tend to be
linked in regulatory pathways to a broad range of other
genes which can be up- or downregulated in a coordinated
manner, isolating the specific mutations producing the resist-
ance has been problematic. Resistance can be tracked by
monitoring the upregulation using qRTPCR, but is not
simply tracked using PCR. The difficulty for field-based ento-
mologists tracking this resistance has resulted in major under-
reporting of the extent and spread of this type of resistance. It
has also made it impossible to draw conclusions from a sys-
tematic review of the impact of pyrethroid resistance on LLIN
efficacy, where there are no data available to track the poten-
tial impact of resistance on disease transmission, and even the
simpler relationship between resistance and entomological
indicators (such as mortality, repellency and blood feeding),
which is apparent in laboratory studies where resistance can
be better characterized, is lost in the noise in the data
connected to inadequate and inaccurate resistance monitoring.
In 2013, a third wave of P450-based metabolic resistance
became apparent in West African An. gambiae. This resistance,
now recorded in Burkina Faso and the Ivory Coast, produces
resistance to pyrethroids an order of magnitude higher again
than that manifest in the more widespread metabolic or
metabolicþ kdr populations. Resistance once selected often
spreads rapidly, as seen by the rapid shifts of insecticidesusceptibility throughout Africa over the past decade and the
switch in countries like Malawi from complete susceptibility to
country wide resistance over the space of less than 12 months.
The levels of resistance (more than 1000-fold) conferred by this
third resistance wave give a high probability that this will
impact on the efficacyof bothpyrethroid-basedbednets and IRS.
In addition to physiological resistance, there is the potential
for behavioural changes in the insect vectors. This is much
more poorly documented, but shifts from indoor biting and
resting to outdoors may be occurring in parts of Africa.3. New interventions on the horizon
Development of new drugs, insecticides and diagnostics will
be needed if we are to maintain current gains and reduce
global burdens of transmission. The risk/reward profiles of
these products are not sufficiently balanced for industry to
embark on this development alone. The estimated size of the
market for crop protection insecticides is approximately US$
8 billion per annum, non-crop insecticides are approximately
US$ 2 billion and vector control is only US$0.2–0.7 billion.
The profit margin in this size of market is not sufficient to war-
rant the risk associated with the US$ 1–200 million cost of
developing a new insecticide. Product Development Partner-
ships (PDPs) have been established to combine public money
with public and private know-how to produce products appli-
cable for use in disease endemic countries. Four PDPs are active
inmalaria, theMedicines forMalaria Venture stimulating drug
development, Malaria Vaccine Initiative for vaccines, the Inno-
vative Vector Control Consortium (IVCC) for insecticides and
vector control diagnostics and the Foundation for Innovative
New Diagnostics for clinical diagnostics.
Pyrethroids were the last mainstream public health insecti-
cide class to be developed, and these have been in use now for
more than 30 years. The primary focus of the IVCC is to work
with industry to develop new insecticide classes to replace the
pyrethroids for both IRS and LLINs [23]. In addition to its
portfolio of new insecticide-based products, it also has a
number of products designed to improve insecticide resistance
monitoring and evaluation, quality assurance of insecticide-
based products in field settings and data systems to draw
together entomological, parasitological, logistics and disease
transmission data (figure 1).
To ensure that we can maintain control in the medium to
long term and establish evidence-based insecticide resistance
management plans, more than a single new insecticide class
will be required, as we already have resistance issues with all
existing public health insecticide classes. Ideally, any new
insecticide should not be introduced as a single treatment,
resulting in a high resistance selection pressure. Introducing
several insecticides in rotation, mosaic or mixture formats
should reduce the likelihood of resistance selection signifi-
cantly, as long as none of the insecticides share a common
target site or metabolic detoxification pathway. The current
portfolio of IVCC projects is designed to produce three new
insecticide classes by around 2023, with no cross-resistance to
current insecticide classes. A range of projects have been devel-
opedwith industrial partners that has resulted inmore than 4.5
million compounds being screened in simple mosquito mor-
tality tests, with the most promising leads taken forward into
further development. An overview of the current portfolio
and projected timelines is given in figure 2.
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Figure 1. Structure and function of the IVCC. (Online version in colour.)
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Figure 2. Overview of the new insecticides portfolio of IVCC products and associated timeframes to get these insecticides to the malaria control market. (Online
version in colour.)
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ment time given the rapid rise and spread of pyrethroid
resistance, but in the interim it is essential that we attempt
to manage the current pyrethroid, organophosphate and
carbamate resistance circulating in the anopheline popu-
lations to maintain control with both LLINs and IRS. This
will require improved monitoring and evaluation of resist-
ance in the field aligned with evidence-based resistance
management strategies, building on an understanding of
local mosquito resistance frequencies, level and operational
impact. Current monitoring activities associated with
almost all programmes are inadequate for this in both scale
and quality. For example, resistance monitoring that relied
entirely on spot bioassays using single ‘discriminating
dosages’ would have picked up the pyrethroid resistance in
West Africa, but would not have registered the shift from
5- to 100- to 1000-fold resistance conferred by the threedifferent waves of resistance that have occurred in countries
such as Ivory Coast. Reliance on kdr PCR monitoring as a
proxy for pyrethroid resistance would have registered the
first wave of resistance, but suggested over time that poten-
tially resistance frequencies were declining as resistance due
to the metabolic systems increased. There is clearly a need
for better informed, more systematic resistance monitoring
with data shared openly so a coordinated response to the
resistance threat can be established. To date, there is little evi-
dence that this will be achieved in the near future despite the
obvious and increasing threat of resistance.
Regulatoryandregistration times for thenew insecticides are
at present estimates. All current public health insecticides have
been introduced from re-purposing of mainstream agro-
chemicals that have followed standard regulatory pathways to
market. These new insecticides will be the first that have been
developed primarily for the public health market, hence there
rstb.royalsociet
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insecticides. Appropriate regulatory bodies such as the Environ-
mental Protection Agency and normative bodies such as the
World Health Organisation Pesticide Evaluation Scheme are
working with the IVCC and other interested parties to look at
the appropriate route to market for these compounds. It islikely that international pressure will be needed to ensure that
we have a safe, effective and timely regulatory and registration
system in place to ensure that these compounds can be used
for disease control in a timeframe that will allow replacement
of pyrethroids before the major malaria reductions we see
today are lost. ypublishing.oReferences rg
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